Patents by Inventor Erica Evans Raab

Erica Evans Raab has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RET inhibitor for use in treating cancer having a RET alteration
    Patent number: 11963958
    Abstract: Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: April 23, 2024
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Erica Evans Raab, Beni B. Wolf
  • RET inhibitor for use in treating cancer having a RET alteration
    Patent number: 11872192
    Abstract: Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: January 16, 2024
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Erica Evans Raab, Beni B. Wolf
  • RET INHIBITOR FOR USE IN TREATING CANCER HAVING A RET ALTERATION
    Publication number: 20220175773
    Abstract: Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
    Type: Application
    Filed: July 16, 2021
    Publication date: June 9, 2022
    Inventors: Erica Evans Raab, Beni B. Wolf
  • RET inhibitor for use in treating cancer having a RET alteration
    Patent number: 11273160
    Abstract: Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: March 15, 2022
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Erica Evans Raab, Beni B. Wolf
  • Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity
    Publication number: 20210290620
    Abstract: This disclosure relates to combinations of RET inhibitors and inhibitors of mTORC1 and their use in the treatment of various cancers mediated by aberrant RET activity. Preferably, the cancer is chosen from thyroid cancer, non-small cell lung cancer, paraganglioma or intrahepatic bile duct carcinoma. The RET inhibitor preferably is BLU-667, and the mTORC1 inhibitor preferably is everolimus or AZD8055.
    Type: Application
    Filed: May 15, 2018
    Publication date: September 23, 2021
    Inventors: Erica Evans Raab, Rami Rahal
  • RET INHIBITOR FOR USE IN TREATING CANCER HAVING A RET ALTERATION
    Publication number: 20210100795
    Abstract: Disclosed herein is the treatment of a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 300 mg to 400 mg of the selective RET inhibitor once daily.
    Type: Application
    Filed: April 3, 2019
    Publication date: April 8, 2021
    Inventors: Erica Evans Raab, Beni B. Wolf
  • RET INHIBITOR FOR USE IN TREATING CANCER HAVING A RET ALTERATION
    Publication number: 20210100799
    Abstract: Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 8, 2021
    Inventors: Erica Evans Raab, Beni B. Wolf
  • RET INHIBITOR FOR USE IN TREATING CANCER HAVING A RET ALTERATION
    Publication number: 20210085680
    Abstract: Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
    Type: Application
    Filed: October 2, 2020
    Publication date: March 25, 2021
    Inventors: Erica Evans Raab, Beni B. Wolf
  • METHODS OF TREATING A BRUTON'S TYROSINE KINASE DISEASE OR DISORDER
    Publication number: 20150216865
    Abstract: The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.
    Type: Application
    Filed: September 3, 2013
    Publication date: August 6, 2015
    Inventors: William Frederick Westlin, III, Erica Evans Raab, Zebulun David Horowitz, Claudia Eve Kasserra, Lisa Beebe, Maria Palmisano, Gondi Nagendra Kumar, Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, Deqiang Niu, Lixin Qiao